Supplement archive

2024


2024, Volume 31, Supplement 3:

Digoxin: its history, modern-day clinical use and toxicity management



2024, Volume 31, Supplement 2:

Embedding innovation in clinical practice to improve patient care across cardiovascular disease



2024, Volume 31, Supplement 1:

Lipoprotein(a) - advances in understanding

2023


2023, Volume 30, Supplement 3:

Inspiring change within the NHS to improve collaborative working and patient care across CVD



2023, Volume 30, Supplement 2:

Managing triglyceride levels to reduce residual cardiovascular risk



2023, Volume 30, Supplement 1:

Overcoming barriers to treating severe aortic stenosis

2022


2022, Volume 29, Supplement 2:

Whats new in heart failure guidance – a users guide

2021


2021, Volume 28, Supplement 1:

Iron deficiency in heart failure

2020


2020, Volume 27, Supplement 2:

Adapting cardiovascular disease care to the new norm of the COVID-19 era – same standard, different delivery



2020, Volume 27, Supplement 1:

Peripheral artery disease in the UK – unmet needs

2019


2019, Volume 26, Supplement 2:

Edoxaban – insights from pivotal studies and sub-analyses



2019, Volume 26, Supplement 1:

Advances in the treatment of chronic heart failure with reduced ejection fraction in real-world settings

2018


2018, Volume 25, Supplement 3:

Advances in cardiac pacing – A 60th anniversary update



2018, Volume 25, Supplement 2:

Management of cardiovascular disease in the patient with diabetes



2018, Volume 25, Supplement 1:

Anticoagulation in atrial fibrillation: focus on PIONEER AF-PCI and its implications

2017


2017, Volume 24, Supplement 1:

Optimising the management of post-ACS patients

2016


2016, Volume 23, Supplement 2:

The future of cardioversion management – new strategies for the use of oral anticoagulation in direct current cardioversion



2016, Volume 23, Supplement 1:

Perspectives in chronic heart failure – new treatment advances

2015


2015, Volume 22, Supplement 1:

Pulmonary hypertension in UK clinical practice – an update

2014


2014, Volume 21, Supplement 2:

Unlocking the potential of NOACs



2014, Volume 21, Supplement 1:

Rivaroxaban in non-valvular atrial fibrillation: European experience

2013


2013, Volume 20, Supplement 3:

Cardiovascular health and disease prevention in clinical practice



2013, Volume 20, Supplement 2:

Acute heart failure – a call to action



2013, Volume 20, Supplement 1:

Optimising hypertension treatment: NICE/BHS guideline implementation and audit for best practice

2012


2012, Volume 19, Supplement 2:

Chronic stable angina guidelines – is there an emerging international consensus?



2012, Volume 19, Supplement 1:

Lipids and CVD: improving practice and clinical outcome

2011


2011, Volume 18, Supplement 3:

The management of stable angina – a perspective on recent guidance



2011, Volume 18, Supplement 2:

Anaemia in chronic heart failure: what constitutes optimal investigation and treatment?



2011, Volume 18, Supplement 1:

Setting the standard for cardiac rehabilitation

2010


2010, Volume 17, Supplement 3:

PCI in the UK – the continuing journey



2010, Volume 17, Supplement 2:

Are all angiotensin receptors blockers the same?



2010, Volume 17, Supplement 1:

Aspirin – reassessing its role in cardiovascular disease

2009


2009, Volume 16, Supplement 3:

Multi-management of ischaemic heart disease: do we have the COURAGE of our convictions?



2009, Volume 16, Supplement 2:

Maximising safety and efficacy in the treatment of wet AMD



2009, Volume 16, Supplement 1:

Moving forward in pulmonary arterial hypertension

2008


2008, Volume 15, Supplement 2:

Cholesterol management



2008, Volume 15, Supplement 1:

Clinical implications of the inhibition of the late sodium current: a new paradigm in the treatment of ischaemic heart disease

2007


2007, Volume 14, Supplement 4:

Direct renin inhibition with aliskiren – a new option in treating hypertension



2007, Volume 14, Supplement 3:

Optimising global risk reduction: insights from REACH



2007, Volume 14, Supplement 1:

Best practice principles for cholesterol lowering

2006


2006, Volume 13, Supplement 2:

The role of angiotensin-converting enzyme inhibitors in coronary artery disease



2006, Volume 13, Supplement 1:

Switching statins: what are the issues and implications?

2005


2005, Volume 12, Supplement 2:

National Institute for Clinical Excellence (NICE) recommendations on the use of myocardial perfusion scintigraphy



2005, Volume 12, Supplement 1:

This House believes that the UK healthcare system may be failing as many as 50% of patients with hyperlipidaemia by not reducing their cholesterol to effective levels

2004


2004, Volume 11, Supplement 3:

A new class in cholesterol management



2004, Volume 11, Supplement 2:

Improved cardiovascular risk reduction: the evidence for raising HDL cholesterol



2004, Volume 11, Supplement 1:

Diet and heart health symposium II

2003


2003, Volume 10, Supplement 4:

Phosphodiesterase type 5 (PDE5) inhibitors: looking beyond erectile dysfunction



2003, Volume 10, Supplement 3:

Drug treatment of hypertension – the future is combination therapy



2003, Volume 10, Supplement 2:

Socratic dialogue: the future management of hyperlipidaemia



2003, Volume 10, Supplement 1:

Diet and heart health: emerging evidence

2002


2002, Volume 09, Supplement 8:

Management of acute coronary artery disease



2002, Volume 09, Supplement 7:

Early thrombolysis – the realities and the practicalities